The dose used in this study (600 mg tiragolumab plus 1200 mg atezolizumab, every 3 weeks) is the same as other studies of tiragolumab, including the phase III studies SKYSCRAPER-01 (NCT04294810; untreated advanced PD-L1-positive NSCLC), SKYSCRAPER-02 (NCT04256421; untreated extensive-stage small cell lung cancer) [29], and SKYSCRAPER-08 (NCT04540211; unresectable advanced esophageal squamous cell carcinoma). Here, CD274 is linked to non-small cell lung carcinoma.